The injection product is a generic equivalent to Sanofi-aventis Lovenox.
Enoxaparin is a low molecular weight heparin for treatment of deep vein thrombosis and prophylaxis of ischemic complications in unstable angina and non-Q-wave myocardial infarction.
The temporary restraining order expires on 21 October.
Watson expects to launch the product during the fourth quarter of 2011 if the plaintiffs’ request for a preliminary injunction is denied, the company said.